What is HC Wainwright’s Estimate for KPTI Q1 Earnings?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) – HC Wainwright raised their Q1 2025 earnings per share estimates for Karyopharm Therapeutics in a research report issued on Thursday, February 20th. HC Wainwright analyst E. White now forecasts that the company will post earnings of ($0.29) per share for the quarter, up from their previous estimate of ($0.31). HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Karyopharm Therapeutics’ current full-year earnings is ($0.71) per share. HC Wainwright also issued estimates for Karyopharm Therapeutics’ Q3 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.10) EPS, FY2026 earnings at ($0.87) EPS and FY2027 earnings at ($0.46) EPS.

Other equities analysts have also issued research reports about the company. Piper Sandler upped their price objective on Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 6th. Royal Bank of Canada reiterated an “outperform” rating and issued a $3.00 target price on shares of Karyopharm Therapeutics in a research report on Thursday, February 20th. Finally, StockNews.com downgraded Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 22nd. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $5.00.

Karyopharm Therapeutics Stock Down 4.1 %

NASDAQ KPTI opened at $0.57 on Monday. The firm has a market cap of $72.07 million, a price-to-earnings ratio of -0.56 and a beta of 0.06. The business has a 50-day moving average price of $0.66 and a 200-day moving average price of $0.75. Karyopharm Therapeutics has a twelve month low of $0.51 and a twelve month high of $1.70.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings results on Wednesday, February 19th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.02. The company had revenue of $30.54 million for the quarter, compared to the consensus estimate of $30.29 million.

Institutional Investors Weigh In On Karyopharm Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Velan Capital Investment Management LP purchased a new stake in Karyopharm Therapeutics during the fourth quarter valued at approximately $27,000. Two Sigma Advisers LP raised its position in Karyopharm Therapeutics by 145.5% during the fourth quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock valued at $52,000 after purchasing an additional 45,400 shares during the period. Two Sigma Investments LP raised its position in Karyopharm Therapeutics by 60.3% during the fourth quarter. Two Sigma Investments LP now owns 137,786 shares of the company’s stock valued at $93,000 after purchasing an additional 51,856 shares during the period. Shay Capital LLC bought a new position in shares of Karyopharm Therapeutics during the fourth quarter valued at approximately $116,000. Finally, Focus Partners Wealth bought a new position in shares of Karyopharm Therapeutics during the fourth quarter valued at approximately $31,000. 66.44% of the stock is currently owned by hedge funds and other institutional investors.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).